M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles

Abstract

Macrophages have been found to be negative predictors of outcome in patients with uveal melanoma. In particular, recent studies point towards a disease-progressing role of proangiogenic M2 macrophages in melanomas with monosomy 3. Although most studies implicate a protective effect of PPAR-gamma activation in tumors, PPAR-gamma has also been shown to promote the polarization of M1 macrophages towards the M2 phenotype. The purpose of this investigation was first, to characterize the phenotype of tumor infiltrating macrophages and second, to study PPAR-gamma expression in uveal melanomas with molecular gene expression profile as prognostic predictors for patients’ outcome. Twenty specimens from patients with uveal melanoma were analyzed for clinical and histologic tumor characteristics. The molecular RNA profile (class 1 or class 2) was commercially determined. Using immunohistochemical techniques, the specimens were dual labeled for CD68 and CD163. CD68+CD163− M1 macrophages and CD68+CD163+ M2 macrophages were analyzed in ten high power fields sparing macrophage-poor areas and a mean value was calculated for each tumor. The tumors were immunostained for von Willebrand factor and the mean vascular density (MVD) was analyzed according to Foss. To assess the proliferative rate of each tumor, Ki67 expression was evaluated in ten high power fields followed by calculation of a mean value. Expression of PPAR-gamma was evaluated using a score from 0 (no staining) to 3 (tumor entirely stained). Statistical analysis and a respective correlation was made between histologic characteristics, molecular profile, type of tumor infiltrating macrophages (M1 versus M2), MVD, proliferative rate, and PPAR-gamma expression. Our results showed a correlation between the ratio of M2/M1 macrophages and the molecular profile with a ratio of approximately 1 corresponding to molecular class 1 and a ratio of approximately 2 corresponding to molecular class 2 (p=0.01). The ratio of M2/M1 macrophages was higher in tumors with extraocular extension (p=0.01). PPAR-gamma was predominantly expressed in the cytoplasm of tumor cells. Its expression showed no association with the molecular RNA profile (p=0.83). This study confirmed that the ratio of M2/M1 macrophages is another prognostic factor in uveal melanoma. Thus, polarization of macrophages plays an important role for patients’ outcome. PPAR-gamma is expressed in uveal melanoma tumor cells and further studies are warranted to determine its role in tumor biology.

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

“…We show for the first time, that intratumoral TLR7/8 agonist shifts the intratumoral M1/M2 macrophage ratio, and importantly, that these macrophages and their chemokine CCL2 are important for tumor control. M2 to M1 polarization of TAMs by 3M-052 holds promise for clinical application, since high M2/M1 TAM ratios are considered as a poor prognostic factor in multiple cancers including cutaneous and uveal melanoma and lung cancer (15, 37–40). In contrast, O'Sullivan et.…”

Innate immunity in cutaneous melanoma

“…Urokinase‐type plasminogen activator receptor and matrix metallopeptidase‐9, which are expressed by both tumour cells and TAMs, enhance tumour invasion . Recent studies show a disease‐progressing role of proangiogenic M2 macrophages in uveal MMs with monosomy 3, and association of TAMs with tumour aggressiveness and poor prognosis in sinonasal MM . Overall, the role of TAMs in cutaneous MM still needs further clarification.…”

Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial

“…Generally, redirecting hallmarks of cancer by communicative reprogramming leads to long‐term tumour control in histologically quite different neoplasias1, 2: A recently published randomized phase II trial on metastatic melanoma revealed significant impact of pioglitazone, a peroxisome proliferator‐activated receptor γ (PPAR γ )3, 4 agonist, on inflammation control, progression‐free survival and overall survival when added to immune‐modulatory and angiostatic acting metronomic low‐dose chemotherapy 5, 6, 7…”